Evidence map›Paper›PMID 34718647›Full record

ArticleThe Journal of infectious diseases2022

Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient.

Jonathan Klein, Anderson F Brito, Paul Trubin, Peiwen Lu, Patrick Wong, Tara Alpert, Mario A Peña-Hernández, Winston Haynes, Kathy Kamath, Feimei Liu and 22 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Reinfection in patients with COVID-19: a systematic review.Global health research and policy · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Laboratory Diagnosis for SARS-CoV-2 Infection.Infectious disease clinics of North America · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors at 3 institutions in 1 country.

Jonathan KleinDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Anderson F BritoDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Paul TrubinDepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Peiwen LuDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Patrick WongDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Tara AlpertDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Mario A Peña-HernándezDepartment of Biological and Biomedical Sciences, Yale University School of Medicine, New Haven, Connecticut, USA.
Winston HaynesSerimmune Inc, Goleta, California, USA.
Kathy KamathSerimmune Inc, Goleta, California, USA.
Feimei LiuDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Chantal B F VogelsDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Joseph R FauverDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Carolina LucasDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Jieun OhDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Tianyang MaoDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Julio SilvaDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Anne L WyllieDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
M Catherine MuenkerDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Arnau Casanovas-MassanaDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Adam J MooreDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Mary E PetroneDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Chaney C KalinichDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Charles Dela CruzDepartment of Medicine, Section of Pulmonary and Critical Care Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Shelli FarhadianDepartment of Internal Medicine, Section of General Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
Aaron RingDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
John ShonSerimmune Inc, Goleta, California, USA.
Albert I KoDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Nathan D GrubaughDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, Connecticut, USA.
Benjamin IsraelowDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Akiko IwasakiDepartment of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA.
Marwan M AzarDepartment of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Yale Implementing Medical and Public Health Action Against Coronavirus in Connecticut (IMPACT) Research Team
Yale University · USSerimmune (United States) · USHoward Hughes Medical Institute · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NRSA Training CoreTL1TR001864 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$9.9M
TRAINING IN THE PATHOGENESIS OF INFECTIOUS DISEASEST32AI007517 · NIAID · YALE UNIVERSITY · PI Jaimie Meyer, Albert C Shaw · 1997 to 2026
$6.1M
Short-Term Reserch Training: Students in Health SchoolsT35HL007649 · NHLBI · YALE UNIVERSITY · PI Sarwat I Chaudhry, Erica L Herzog · 1987 to 2026
$5.7M
Innate Control of Adaptive Immunity to SARS-CoV-2K08AI163493 · NIAID · YALE UNIVERSITY · PI GOLDMAN-ISRAELOW, BENJAMIN · 2021 to 2025
$969k
CDC HHS 75D30120C09570National Institute of Allergy and Infectious Diseases 2T32AI007517-16NCATS NIH HHS TL1 TR001864NCATS NIH HHS UL1 TR001863NHLBI NIH HHS T35 HL007649NIAID NIH HHS K08 AI163493NIAID NIH HHS T32 AI007517
6 · The paper itself

Abstract

backgroundThe underlying immunologic deficiencies enabling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfection are currently unknown. We describe deep longitudinal immune profiling of a transplant recipient hospitalized twice for coronavirus disease 2019 (COVID-19).

methodsA 66-year-old male renal transplant recipient was hospitalized with COVID-19 March 2020 then readmitted to the hospital with COVID-19 233 days after initial diagnosis. Virologic and immunologic investigations were performed on samples from the primary and secondary infections.

resultsWhole viral genome sequencing and phylogenetic analysis revealed that viruses causing both infections were caused by distinct genetic lineages without evidence of immune escape mutations. Longitudinal comparison of cellular and humoral responses during primary SARS-CoV-2 infection revealed that this patient responded to the primary infection with low neutralization titer anti-SARS-CoV-2 antibodies that were likely present at the time of reinfection.

conclusionsThe development of neutralizing antibodies and humoral memory responses in this patient failed to confer protection against reinfection, suggesting that they were below a neutralizing titer threshold or that additional factors may be required for efficient prevention of SARS-CoV-2 reinfection. Development of poorly neutralizing antibodies may have been due to profound and relatively specific reduction in naive CD4 T-cell pools. Seropositivity alone may not be a perfect correlate of protection in immunocompromised patients.

Indexed as

COVID-19ReinfectionTransplant RecipientsAgedAntibodies, NeutralizingAntibodies, ViralHumansMaleOrgan TransplantationPhylogenySARS-CoV-2Antibodies, NeutralizingAntibodies, Viralhumoral responseimmunocompromisedneutralizing antibodiesreinfectionSARS-CoV-2transplant

Identifiers

PMID34718647
PMCPMC8807168
OpenAlexW3209223190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.